Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Your RPS

Review of COVID-19 disparities just 'restating problem', says RPS

Sandra Gidley, president of the Royal Pharmaceutical Society said “the outcome of this review is disappointing as it restates the problem, rather than offering new insight”.

Sandra Gidley

Source: Nic Bunce / The Pharmaceutical Journal

Sandra Gidley, president of the Royal Pharmaceutical Society has stated that the Society will be taking the issue up with Victoria Atkins, the equalities minister

The Royal Pharmaceutical Society (RPS) has accused Public Health England (PHE) of offering “no new insight” into the problem of how COVID-19 affects black, Asian, and minority ethnic (BAME) groups.

The report Disparities in the risk and outcomes of COVID-19, published by PHE on 2 June 2020, states that “the impact of COVID-19 has replicated existing health inequalities and, in some cases, has increased them”.

Data cited in the review, from bodies including the Office for National Statistics and the Intensive Care National Audit and Research Centre, show that the risk of death among those diagnosed with COVID-19 was higher in people from BAME groups compared to white ethnic groups, even when other variables including sex, age, socioeconomic deprivation and region were accounted for.

“The outcome of this review is disappointing as it restates the problem, rather than offering new insight,” said Sandra Gidley, president of the RPS.

“We had hoped for an action plan to address the issues for BAME patient-facing frontline clinicians. The report contains no recommendations or actions, and it is unclear how the government plans to proceed.”

In the review, PHE say that its findings — based on surveillance data available to PHE at the time of publication — “improve our understanding of the pandemic and will help in formulating the future public health response to it”.

Gidley said that the government must “act much more quickly on this issue”, and that the “first step on from this report must be to ensure robust risk assessment and protection is in place for BAME staff along with other vulnerable groups, such as staff with existing health conditions”.

Gidley added that the Society will be taking the issue up with Victoria Atkins, equalities minister, “as a matter of urgency”.

 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2020.20208038

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
PJJ Static MPU
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.